Confirmed compositions: Methylprednisolone IP 4 mg and 8 mg, excipients q.s.
Usage: Certain forms of arthritis and other clinician-selected inflammatory or allergic disorders.
Category: Anti Allergic Drugs
Therapeutic category: Corticosteroid / Glucocorticoid
Manufacturer: Healthy Life Pharma Pvt. Ltd. (as supplied; WHO-GMP certification to be verified)
Exporter: Healthy Inc (as supplied)
SKU: Methyl Prednisolone Tablets
Methylprednisolone Tablets IP is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Methylprednisolone is a prescription glucocorticoid with anti-inflammatory and immunosuppressive effects. It is used in selected allergic, rheumatologic, respiratory, dermatologic and autoimmune disorders when systemic corticosteroid therapy is clinically appropriate.
Healthy Life Pharma Pvt. Ltd. is identified as manufacturer and Healthy Inc as exporter in the supplied product information. Manufacturing certifications, facility location, market approvals and supply capabilities should be confirmed from current documentation.
| Product name | Methylprednisolone Tablets IP |
|---|---|
| Composition 1 | Each uncoated tablet contains Methylprednisolone IP 4 mg; excipients q.s. |
| Composition 2 | Each uncoated tablet contains Methylprednisolone IP 8 mg; excipients q.s. |
| Dosage form | Uncoated tablets |
| Standard | IP (as supplied) |
| Therapeutic class | Systemic corticosteroid / glucocorticoid |
| CAS number | 83-43-2 |
| Indications | Selected inflammatory, allergic and autoimmune conditions, according to approved labeling |
| Other strengths | 16 mg and 32 mg mentioned in draft description but not confirmed by supplied compositions |
| Packaging / shelf life | To be verified from approved product records |
| SKU | Methyl Prednisolone Tablets |
Low-dose corticosteroid tablet manufacture requires validated blending, content uniformity, contamination control, compression and stability procedures. Specific equipment, dedicated containment suites, granulation methods and taper-pack availability should only be claimed if supported by manufacturer records.
Quality testing should follow the applicable approved Indian Pharmacopoeia monograph and registered product specification. Relevant controls may include identity, assay, content uniformity, dissolution, related substances and stability. Do not assume universal release percentages or assay ranges without the validated product specification.
Methylprednisolone binds intracellular glucocorticoid receptors and modifies inflammatory and immune responses. Clinicians may prescribe it for certain arthritis conditions, asthma exacerbations and other inflammatory or autoimmune disorders. It does not replace epinephrine in anaphylaxis or other emergency first-line treatment.
Its lower mineralocorticoid activity than some other corticosteroids does not eliminate risks of fluid retention, hypertension or cardiovascular complications.
Product registration, dossier format (CTD/ACTD), Certificate of Pharmaceutical Product, certificate of analysis, Free Sale Certificate, WHO-GMP evidence, and export arrangements are subject to availability and destination-country requirements. Request current authenticated documents before procurement or marketing.
What is methylprednisolone used for? It is prescribed for selected inflammatory, allergic and autoimmune conditions, including some forms of arthritis.
Can it be stopped suddenly? The need for tapering depends on dose, duration, repeated courses and patient factors. Prolonged or high-dose therapy should not be stopped abruptly without medical advice; a short course does not always require tapering.
Does it cause weight gain? Increased appetite, weight gain and fluid retention can occur, particularly with prolonged use.
Is it the same as Medrol? Medrol is a brand of methylprednisolone. Equivalence of a specific generic product requires applicable regulatory evidence.
Dose, frequency and duration vary substantially with the condition, severity and patient response. Follow the prescribing clinician and the approved local product label; no universal daily dose or automatic six-day taper applies to all patients. Tablets are taken orally, often with food to reduce gastrointestinal discomfort.
Potential adverse effects include increased blood glucose, mood or sleep changes, stomach irritation, increased infection susceptibility, elevated blood pressure and fluid retention. Longer-term therapy may cause adrenal suppression, osteoporosis, cataracts or glaucoma. Use caution with diabetes, active infection, peptic ulcer disease and interacting medicines such as NSAIDs. Live vaccines may be inappropriate during immunosuppressive corticosteroid dosing. Seek urgent care for severe infection, gastrointestinal bleeding or significant psychiatric symptoms.
Store according to the approved IP product label in the original container, protected from excess heat and moisture. Any specific temperature limit or expiry period must be supported by approved stability data.